A5009498852- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Circular RNAs in diseases
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Cancer-related gene regulation
- Ear Surgery and Otitis Media
- Sinusitis and nasal conditions
- Olfactory and Sensory Function Studies
- Allergic Rhinitis and Sensitization
- Pancreatic and Hepatic Oncology Research
- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Power System Reliability and Maintenance
- Immune cells in cancer
- Enzyme Structure and Function
- Extracellular vesicles in disease
Guangzhou University of Chinese Medicine
2025
Anhui Medical University
2022-2024
First Affiliated Hospital of Anhui Medical University
2024
Beijing Children’s Hospital
2020-2023
Capital Medical University
2020-2023
Jilin Province Tumor Hospital
2014-2022
Shanghai Changzheng Hospital
2016-2021
Millennium Engineering and Integration (United States)
2021
Second Military Medical University
2016-2020
Hong Kong Polytechnic University
2019
Abstract INTRODUCTION With the advancement of disease‐modifying therapies for Alzheimer's disease (AD), validating plasma biomarkers against cerebrospinal fluid (CSF) and positron emission tomography (PET) standards is crucial in both research real‐world settings. METHODS We measured phosphorylated tau (p‐tau)217, p‐tau181, amyloid beta (Aβ)1‐40, Aβ1‐42, neurofilament light chain cohorts. Participants were categorized by brain status using US Food Drug Administration/European Medicines...
Background/Aims: Nasopharyngeal cancer (NPC) is one of the common human malignant diseases all over world, and chemotherapy remains main therapy for NPC. However, survival life quality NPC patients are still very poor. Thus, novel selective anti-tumor agents pressingly needed. Our previous study identified pectolinarigenin as a effective drug candidate In this study, we further investigated its activities explored potential molecular mechanism. Methods: C666-1 cells were cultured treated by...
// Yin Cheng 1 , Haiyan Yang Sun Hongkai Zhang Shuangni Yu Zhaohui Lu and Jie Chen Department of Pathology, Peking Union Medical College Hospital, Chinese Academy Sciences College, Beijing, China Correspondence to: Chen, email: xhblk@163.com Keywords: pancreatic ductal adenocarcinoma (PDAC); miR-93; RUNX1; HMGA2 (High mobility group AT-hook 2); tumor progression Received: June 13, 2017 Accepted: July 26, Published: August 24, ABSTRACT Runt-related transcription factor 1(RUNX1), a key in...
In total, 95% of primary tumors in the pancreas are epithelial tumors; mesenchymal at this site extremely rare. At present, only one comprehensive study about these rare has been performed. Another retrospective analysis is performed present study, which, to best our knowledge, first be China. 10 patients that underwent resection for were identified a 15-year period Chinese Academy Medical Sciences and Peking Union College, which accounted 0.51% total surgically resected hospital. Among...
Abstract A close relation between microRNA-151a-3p (miR-151a-3p) and nasopharyngeal carcinoma (NPC) has been reported, however, the molecular mechanism is still unclear. The aim of present study was to explore in promotion miR-151a-3p NPC progression. levels miR-151-3p several cell lines were detected order screen an experimental line. MiR-151a-3p mimic inhibitor constructed transfected into 5-8F cells proliferation by Cell Counting Kit-8 (CCK-8). apoptosis rate, migration invasion...
The prevention of chemotherapy-induced nausea and vomiting was one the most challenging supportive care issues in oncology, especially to highly emetogenic chemotherapy (HEC). A total 645 patients were randomized into fosaprepitant group (fosaprepitant/placebo 150 mg d1 combination with granisetron dexamethasone) or aprepitant (aprepitant/placebo 125 d1; 80 d2-d3 plus dexamethasone).The primary endpoint percentage who had a complete response (CR) over entire treatment course (0-120 hr,...
Non-Hodgkin's lymphoma (NHL) primarily derived from the base of tongue, is rare. Human papillomavirus (HPV) and Epstein-Barr virus (EBV) are important aetiological risk factors for tumours head neck. This study describes clinicopathological features NHL in tongue status HPV EBV these cases.Seven cases were identified Pathological Registry Database at Peking Union Medical College Hospital (PUMCH). The utilized immunochemistry, situ hybridization (ISH), gene rearrangement to confirm disease...
Nasopharyngeal cancer is one of the most common malignant tumors in head and neck. Identification promising miRNA biomarkers might benefit a lot to detection nasopharyngeal carcinoma. expression profile clinical information were obtained from two microarray profiling data sets Gene Expression Omnibus (GEO) database. signature model was constructed via univariate Cox survival analysis, multivariate least absolute shrinkage selection operator regression analysis. Kaplan–Meier curve, area under...
Abstract Primary cutaneous amyloidosis (PCA) is a chronic pruritic skin disease. The apple‐green birefringence of Congo red‐stained amyloid under polarized light microscope (CR‐PLM) remains the gold standard in diagnosis PCA. However, there are some limitations to this approach. In study, eighty‐two paraffin‐embedded biopsy samples were collected from patients with clinical sections respectively stained hematoxylin–eosin (HE), crystal violet (CV), and red (CR) observed microscope. CR‐stained...
7605 Background: About 20–30% of all pts with NSCLC develop BM, leading to a poor prognosis and median survival <6 months after whole brain radiotherapy. The role systemic CT in the management BM is limited controversial. CTONG0803 study (NCT00663689) was designed evaluate 2nd-line erlotinib BM. Methods: Eligible had confirmed adenocarcinoma or activating EGFR mutation-positive asymptomatic (≥1 lesion ≥10mm diameter ≥3 lesions <10mm); without extracranial progressive disease (PD) 2–6 cycles...